We have been asked by a number of our members if we know anything about the about the progress of the LX211 trials which highlighted LX211 as potential disease modifying therapy for noninfectious uveitis. Birdshot is a non infectious form of posterior uveitis.
In February we read that Lux Biosciences was preparing to file for US and European approval. If the drug is approved it will be the first drug licencensed in the US and Europe specifically for uveitis. We would assume that licencing in the UK would be likely to follow this.
On 4th August, Isotechnika Pharma Inc, Lux’s US partners sent out a press release which stated that before approval would be given in the US, further trials were needed to check out the drugs safety. It stated that approval remained on course for Europe. http://micro.newswire.ca/release.cgi?rkey=1808048256&view=64134-0&Start=0&htm=0
We are not sure how long the process takes for licencing to occur but we are watching out for developments.